Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Their perilous situation is attributed primarily to the over-harvesting of their eggs during the last century. And though their nesting grounds are protected and many commercial fishing fleets now use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results